期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

孕妇尿液cfDNA产前检测胎儿21-三体可行性研究

The feasibility analysis of prenatal testing of fetal trisomy 21 using cfDNA in the urine of pregnant women
原文传递
导出
摘要 目的本文旨在探讨利用大规模平行测序(MPS)技术对孕妇尿液中的游离DNA(cf DNA)进行胎儿21-三体(T21)无创产前检测的可行性。方法本研究选取10个胎儿羊膜穿刺核型分析结果正常和9个分析结果为T21的孕妇晨尿,对19个孕妇的尿液采用磁珠法提取cf DNA,构建文库,Hisq2000测序,测序结果用BWA软件比对序列,计算每个样本的21号染色体所的比对上的唯一读长(Read)比率,最后进行Mann-Whitney U-test检测分析两组样本是否有显著差异。结果胎儿21-三体的孕妇尿液cf DNA中21号染色体的百分含量与胎儿正常孕妇的有显著差异(P=0.04122)。结论对孕妇尿液中的游离DNA进行大规模平行测序可用于无创产前检测21-三体。 Objective：This study will analyze the feasibility of noninvasive prenatal testing of fetal trisomy 21（T21）by massively parallel sequencing（MPS）of cell-free DNA（cf DNA）in the maternal urine. Methods：In this research,10 normal samples and 9 T21 samples validated by amniocentesis and karyotype analysis were selected for the prediction. For each sample,at least 5M reads was obtained,and unique mapping rate was calculated. Mann-Whitney U-test was used to analyze whether there is significant difference between two groups. Results：The cf DNA percentage of 21 chromosome in the maternal urine between having T21 fetal and normal one had significant difference（P=0.03502）. Conclusion：Noninvasive prenatal testing of fetal trisomy 21 by MPS of cfDNA in maternal urine is feasibility.
作者 胡芙蓉 苗正友 宋勤浩 周赤燕
机构地区 浙江省嘉兴市第一医院检验科 浙江省嘉兴市妇幼保健院产前诊断中心
出处 《中国优生与遗传杂志》 2015年第11期10-12,共3页 Chinese Journal of Birth Health & Heredity
关键词 cfDNA 尿液 21-三体 无创产前检测 cfDNA Urine Trisomy 21 Noninvasive prenatal testing
分类号 R714.5 [医药卫生—妇产科学]
  • 相关文献

参考文献21

  • 1苗正友,刘霞,石统昆,葛嘉美,徐营.早、中孕期整合筛查唐氏综合征[J].中华医学杂志,2011,91(3):185-188. 被引量：16
  • 2苗正友,葛加美,张卫华,李素萍,刘晓丹.应用大规模平行基因组测序技术无创产前诊断胎儿常见染色体非整倍体异常[J].中华医学杂志,2014,94(23):1788-1790. 被引量：17
  • 3Lo YM, Corbetta N, Chamberlain PF, et al. Presence of fetal DNA in maternal plasma and serum[J]. Lancet, 1997,350 (9076) : 485-487.
  • 4Chiu WK, Chan KCA, Gao Y, et al. Noninvasive prenatal diagnosis of fetal chromosomal aneuploidy by massively parallel genomic sequencing of DNA in maternal plasma[J]. PNAS, 2008, 105 ( 51 ) : 20458-20463.
  • 5Tsui NBY, Jiang PY, Chow KCK, et al. High Resolution Size Analysis of Fetal DNA in the Urine of Pregnant Women by Paired- End Massively Parallel Sequencing[J]. PLoS One, 2012,7 (10) : e48319.
  • 6Tryggvason K, Wartiovaara J. How does the kidney filter plasma? [J]. Physiology (Bethesda), 2005, 20:96-101.
  • 7Cherepanova A, Tamkovich S, Pyshnyi D, et al. Immunochemical assay for deoxyribonuclease activity in body fluids[J]. J Immunol Methods, 2007, 325:96-103.
  • 8Bianchi DW, Platt LD, Goldberg JD, et al. Genome-wide fetal aneuploidy detection by maternal plasma DNA sequencing[J]. Obstet Gynecol, 2012, 119:890-901.
  • 9Botezatu I, Serdyuk O, Potapova G, et al. Genetic analysis of DNA excreted in urine :a new approach for detecting specific genomic DNA sequences from cells dying in an organism[J]. Clin Chem, 2000, 46:1078-1084.
  • 10Zheng YWL, Chan KCA, Sun H, et al. Nonhematopoietically derived DNA is shorter than hematopoietically derived DNA in plasma :a transplantation model[J]. Clin Chem, 2012,58:549-558.

二级参考文献22

  • 1Merkatz IR,Nitowski HM,Macri JN,et al.An association between low maternal serum r-fetoprotein and fetal chromesome abnormalities.Am J Obstet Gynecol,1984,148:886.
  • 2Knight GJ,Palomarki GE,Haddow JE.Use of maternal serum α-fetaprotein measurements to screen for Down syndrome.Clin Obstet Gynecol,1988,31:36-39.
  • 3Okun N,Summers AM,Hoffman B,et al.Prospective experience with integrated prenatal screening and First-trimester combined screening for trisomy 21 in a large Canadian urban center.Prenat Diagn,2008,28:987-992.
  • 4Cicero S,Bindra R,Remboukos G,et al.Integrated ultrasound and biochemical screening for trisomy 21 using fetal nuchal translucency,absent fetal nasal bone,free beta-hCG and PAPP-A at 11 to 14 weeks.Prenat Diagn,2003,23:306-310.
  • 5Wapner R,Thom E,Simpson JL,et al.First-trimeste screening for trisomy 21 and 18.N Engl J Med,2003,349:1405-1413.
  • 6Malone FD,Canick JA,Ball RH,et al.First-trimester or secondtrimester screening,or both,for Down's syndrome.N Engl J Med,2005,353:2001-2011.
  • 7Borrceell A.Promises and pilfalls of First-trimester songraphic markers in the detection of fetal aneuploidy.Prenat Diagn,2009,29:62-68.
  • 8Vadiveloo T,Crossleg JA,Aitken DA.First-trimester contingent screening for Down's syndrome can reduce the number of nuchal transluliency measure meats required.Prenat Diagn,2009,29:79-82.
  • 9Permi SC,Predanic M,Kalish RB,et al.Clinical use of Firsttrimester aneuploidy screening in a united states population can replicate data from clinical trials.Am J Obstet Gynecol,2006,194:127-130.
  • 10Wald NJ,Watt HC,Hackshaw AK.Integrated screening for Down's syndrome on the basis of tests performed during the first and second trimesters.N Engl J Med,1999,341:461-467.

共引文献30

中国优生与遗传杂志
2015年 第11期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部